Anavex Life Sciences Corp (AVXL)

[kevindenver]

Anavex provided answers and reduced the Uncertainty spun by the FUD narrative. Trofinetide was approved on the same endpoints Anavex will also be using, thus, for the final analysis, there is more clarity now than the uncertainty your comment is elicits.

Though it does call into question whether the Avatar endpoints are adequate for Anavex to claim its a phase 3 rather than a 2b.

coprimary RSBQ and CGI-I change in means vs. RSBQ-AUC

IMO the combined data package of adult and pediatric study analysis will lead to a Rett Syndrome approval regardless of if the adult trial is considered a P3 or not.